KentDMSaverJLKasnerSE, et al. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke. JAMA2021; 326: 2277–2286.
2.
GoessingerBGreiseneggerSKastlS, et al. Stroke recurrence after transcatheter PFO closure in patients with cryptogenic stroke. Int J Stroke2025; 20: 450–460.
3.
SørensenHGroveELHojbjergJAAndersenANielsen-KudskJESimonsenCZ.Recurrent ischemic stroke/transient ischemic attack after patent foramen ovale closure: a cohort study. Int J Stroke2025; 20: 196–204.
4.
CasoVTurcGAbdul-RahimAH, et al. European Stroke Organisation (ESO) Guidelines on the diagnosis and management of patent foramen ovale (PFO) after stroke. Eur Stroke J2024; 9: 800–834.
5.
JazayeriSBPhanCGhozyS, et al. Outcomes of patent foramen ovale closure in patients over 60 years with cryptogenic stroke: a systematic review and meta-analysis. Int J Stroke2025; 21: 603–612.
6.
LarssonPBidondeJOlsenU, et al. Association of post-stroke fatigue with physical activity and physical fitness: a systematic review and meta-analysis. Int J Stroke2023; 18: 1063–1070.
7.
MeadGESposatoLASampaio SilvaG, et al. A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization. Int J Stroke2023; 18: 499–531.
8.
LinYNViswanathanAOgawaEF, et al. Effect of protein supplementation on cardiorespiratory fitness with aerobic training in chronic stroke: a multicenter randomized controlled trial. Int J Stroke2025; 21: 613–624.
9.
ZhangDZhaoZQianY, et al. Low-dose rivaroxaban plus antiplatelet therapy for symptomatic intracranial atherosclerotic stenosis: a prospective cohort study. Int J Stroke. Epub ahead of print 5 February 2026. DOI: 10.1177/17474930261423387.
10.
HohBLMartinRHYeattsSD, et al. Design and early progress of the Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial. Int J Stroke2025; 20: 623–628.
11.
HuXZhangZLiuC, et al. PCSK9 Inhibitor with Statin Therapy for Intracranial Artery Stenosis (PISTIAS): rationale and design of a multicenter randomized controlled trial. Int J Stroke2024; 19: 1071–1076.
12.
LengXSuiBLiuC, et al. Chinese guidelines for diagnosis and treatment of intracranial atherosclerotic stenosis. Int J Stroke. Epub ahead of print 22 January 2026. DOI: 10.1177/17474930261419812.
13.
LiuYZouYZhouH, et al. Prognosis of incidentally detected asymptomatic intracranial atherosclerotic stenosis: a prospective hospital-based cohort study. Int J Stroke2025; 21: 625–634.
14.
CampbellBC.Hyperacute ischemic stroke care-Current treatment and future directions. Int J Stroke2024; 19: 718–726.
15.
LiKSunDWangM, et al. Significance of occlusion site on outcomes in stroke patients with large infarction undergoing endovascular therapy: a prespecified subgroup analysis of the ANGEL-ASPECT trial. Int J Stroke2025; 21: 676–687.
16.
MuirKW.Should we switch to tenecteplase for all ischemic strokes? Evidence and logistics. Int J Stroke2025; 20: 261–267.
17.
ZhouYHeYCampbellBCV, et al; HOPE Investigators. Alteplase for acute ischemic stroke at 4.5 to 24 hours: the HOPE randomized clinical trial. JAMA2025; 334: 788–797.
18.
LiegeoisCAltersbergerVGerschenfeldG, et al. Tenecteplase or alteplase for acute ischemic stroke beyond 4.5 hours of last known well: a pooled analysis of the TETRIS and EVATRISP registries. Int J Stroke2025; 21: 667–675.
19.
ZhouZGeYYoshimuraS, et al. Intravenous thrombolysis in patients with acute ischemic stroke and cerebral microbleeds: results from the ENCHANTED trial. Int J Stroke2025; 21: 657–666.
20.
MarkusHSde LeeuwFE.Cerebral small vessel disease: recent advances and future directions. Int J Stroke2023; 18: 4–14.
21.
ZhangPLuoBZhangP, et al. Impact of small vessel disease on patient outcomes after intravenous thrombolysis for acute ischemic stroke. Am J Cardiol2025; 240: 76–81.
22.
MeyerLGellißenSThomallaG, et al. Reperfusion-dependent treatment effects of thrombectomy in patients with large ischemic infarcts. Int J Stroke2025; 21: 646–656.
23.
TaoCLiuTSunJ, et al. Advancing stroke safety and efficacy through early tirofiban administration after intravenous thrombolysis: the multicenter, randomized, placebo-controlled, double-blind ASSET IT trial protocol. Int J Stroke2025; 20: 373–377.
24.
ZhengLLiuYNieX, et al. Intravenous tirofiban following endovascular therapy for patients with acute large vessel occlusion stroke. Int J Stroke2025; 21: 635–645.
25.
FeiginVLBraininMNorrvingB, et al. World stroke organization: global stroke fact sheet 2025. Int J Stroke2025; 20: 132–144.
26.
CaiYMokVCTMarkusHS.Vascular dementia: world stroke organization fact sheet 2026. Int J Stroke2026; 21: 152–163.
27.
NelsonMFredin GrupperMMVan der WorpH, et al. The importance of advocacy in advancing stroke care: the Global Stroke Action Coalition. Int J Stroke2026; 21: 584–590.
